Moscow-Sana
The Russian Direct Investment Fund confirmed today that a small clinical study of vaccination with the AstraZeneca vaccine and then Sputnik Lite to prevent the Corona virus showed a significant growth of antibodies in the participants.
The TASS news agency quoted the investment fund as saying today, "The results of the interim analysis showed a four-fold or more increase in neutralizing antibodies to protein (S) in the SARS Cove 2 virus in 85 percent of the volunteers on the 57th day of the study."
The results of the study were based on the data of 20 people out of 100 who participated in it, and it began in Azerbaijan last February, where these participants received a dose of AstraZeneca vaccine first, and then a dose of the Russian Sputnik Lite vaccine after 29 days.
